|James A. Bianco, M.D.|
CTI Principal Founder, Chief Executive Officer, and Director
James A. Bianco, M.D. is the principal founder of Cell Therapeutics, Inc. and served as the Company's President and Chief Executive Officer and Director from February 1992 to July 2008. He now serves as CTI’s CEO and Director. Dr. Bianco has been responsible for securing more than $1 billion in operating capital and is the chief architect of the company’s portfolio strategy, leading the acquisition, development, and commercialization of novel agents that improve the safety and efficacy...
|Vartan Gregorian, Ph.D.|
Director; President, Carnegie Corporation
Vartan Gregorian, Ph.D. has been a CTI director since December 2001. He is the twelfth president of Carnegie Corporation of New York, a grant-making institution founded by Andrew Carnegie in 1911. Prior to his current position, which he assumed in June 1997, Gregorian served for nine years as Brown University’s sixteenth president.
He was awarded a Ph.D. in history and humanities from Stanford University. He was founding dean of the Faculty of Arts and Sciences at t...
|Richard L. Love|
Director; Managing Partner, Translational Accelerator LLC
Richard L. Love has been one of our directors since September 2007. Mr. Love is presently a manager of Translational Accelerators, LLC. Mr. Love is also a director of PAREXEL International Corporation (NASDAQ: PRXL), a publicly traded company, and is a director of the following private companies: Applied MicroArrays Inc., PMed Management LLC, SynDevRx Inc., Cancer Prevention Pharmaceuticals Inc. and CerRx Inc. He was previously a director of ImaRx Therapeutics Inc., and, prio...
|Mary O'Neil Mundinger, D.P.H.|
Director; Dean of the Columbia University School of Nursing
Mary O'Neil Mundinger, DrPH, RN, has been one of our directors since April 1997. From 1986 to 2010, she was a dean and professor at the Columbia University School of Nursing and an associate dean on the faculty of medicine at Columbia University. In July 2010, Dr. Mundinger was appointed the Edward M. Kennedy Professor in Health Policy and Dean Emeritus at the Columbia University School of Nursing. Dr. Mundinger has served on the board of directors of United Health Group and Gentiva He...
|Jack W. Singer, M.D.|
CTI Founder and Director, EVP, Global Medical Affairs and Translational Medicine
Jack W. Singer, M.D. is one of the Company’s founders and directors and currently serves as the Company’s Executive Vice President, Global Medical Affairs and Translational Medicine. Dr. Singer has been one of the Company’s directors since its inception in September 1991.From 2004 to June 2012 Dr. Singer was the Company's Chief Medical Officer. From July 1995 to January 2004, Dr. Singer was the Company’s Executive Vice President, Research Program Chairman, and from April 1992...
|Frederick W. Telling, Ph.D.|
Director; Former Director, VP of Corporate Policy and Strategic Management, Pfizer Inc
Frederick W. Telling, Ph.D. has been one of our directors since December 2006. Prior to his retirement in 2007, Dr. Telling was a corporate officer of Pfizer, most recently as Vice President of Corporate Policy and Strategic Management since 1994. He joined Pfizer in 1977 and was responsible for strategic planning and policy development throughout the majority of his career. He currently serves as Chairman of Oragenics Inc. and on the board of directors of Eisai N.A., and Aeq...
|Reed V. Tuckson, M.D., F.A.C.P. |
Director; Executive Vice President and Chief of Medical Affairs at UnitedHealth Group
Reed V. Tuckson, M.D., F.A.C.P. has been one of our directors since September 2011. Dr. Tuckson serves as the Managing Director of Tuckson Health Connections, a private consulting company. From December 2006 to March 2014, Dr. Tuckson served as the Executive Vice President and Chief of Medical Affairs of UnitedHealth Group and, from November 2000 to December 2006, he served as Senior Vice President of Clinical Affairs of UnitedHealth Group. Dr. Tuckson also served as Senior V...
|Matthew D. Perry|
|Mr. Perry has been one of our directors since January 2016. Mr. Perry is the President of BVF Partners L.P. and portfolio manager for the underlying funds managed by the firm. BVF Partners is a private investment partnership that has focused on small-cap, value oriented investment opportunities for more than 20 years. Mr. Perry joined BVF Partners in December 1996 and has been a successful lead investor in dozens of transactions and has positively influenced corporate direction for numerous biot... |
|Michael A. Metzger|
|Mr. Metzger joined CTI BioPharma’s Board in January 2017. Mr. Metzger is currently president and chief operating officer of Syndax Pharmaceuticals, Inc., a publicly traded immuno-oncology biopharmaceutical company. Mr. Metzger served as president and chief executive officer of Regado Biosciences, Inc., a former publicly traded biotechnology company, from 2013 to 2015, where he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015 and acted as an advisor to Tobira during ... |
|David R. Parkinson, M.D.|
|Dr. Parkinson has been one of our directors since June 2017. Dr. Parkinson has served as President and Chief Executive Officer Essa Pharmaceuticals, Inc. since 2016. Dr. Parkinson has served as a venture partner at New Enterprise Associates (NEA), Inc. since 2012 and in 2016 moved to the role of venture advisor to NEA. From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, a biotechnology company focused on the biological characterization of signaling pathways in patients w... |
|Laurent Fischer, M.D.|
|Dr. Fischer has been one of our directors since July 2017. Dr. Fischer was appointed Senior Vice President, Head of the Liver Therapeutic Area at Allergan following the acquisition of Tobira Therapeutics. Dr. Fischer has served as a Senior Advisor on the Frazier Healthcare Partners’ Life Sciences team since March 2017. He was previously chairman and CEO of Jennerex, Inc., a company with a first-in-class oncolytic immunotherapy for Liver Cancer acquired for $150 million by Sillajen. He was co-fou... |